Press Releases

News Brief

Samsung Biologics signs MOU with Sartorius to enhance supply chain for biomedicines

The Singing Ceremony Memorandum of Understanding(MOU) sartorius & Samsung Biologics November 12, 2020 Songdo, Korea
 

 

Samsung Biologics signed an MOU with Sartorius, a German life science company, on November 2012 with shared aims to further strengthen the supply chain for biomedicines. With Sartorius' announcement to invest $100 million in South Korea's bio cluster, Songdo, to build a bio-process manufacturing facility for equipment and materials, it plans to supply materials such as disposable bags, cell culture media, and filters to Samsung Biologics. The facility will be built on a site in Songdo of 24,333㎡ land size and the construction is expected to be completed by 2022. 

 

Satorius is a global company which supplies equipment for leading biotech companies and currently has more than 60 sites worldwide. The rapid growth of the Korean bio industry and the collaborative efforts with IFEZ have positively affected the German company's decision to make a bold investment. Upon MOU agreement, it is expected to further stabilize the supply of biomedicines and enhance the competitive pricing in the market. 

The Singing Ceremony Memorandum of Understanding(MOU) sartorius & Samsung Biologics November 12, 2020 Songdo, Korea
 

 

Samsung Biologics signed an MOU with Sartorius, a German life science company, on November 2012 with shared aims to further strengthen the supply chain for biomedicines. With Sartorius' announcement to invest $100 million in South Korea's bio cluster, Songdo, to build a bio-process manufacturing facility for equipment and materials, it plans to supply materials such as disposable bags, cell culture media, and filters to Samsung Biologics. The facility will be built on a site in Songdo of 24,333㎡ land size and the construction is expected to be completed by 2022. 

 

Satorius is a global company which supplies equipment for leading biotech companies and currently has more than 60 sites worldwide. The rapid growth of the Korean bio industry and the collaborative efforts with IFEZ have positively affected the German company's decision to make a bold investment. Upon MOU agreement, it is expected to further stabilize the supply of biomedicines and enhance the competitive pricing in the market.

SITE MAP

close
Close

Your download is ready

Click Download.

Close

Subscribe to Our Newsletter

Please fill in your details, select one or more areas of interest, and click the subscribe button to receive our newsletter.

Subscribe to Our Newsletter
  • Privacy Policy to collect the email address that I have provided until I withdraw my consent. The collected information will only be used for the purpose of mailing service. If you do not wish to consent, you will not be able to receive the newsletter. Samsung Biologics respects the privacy of its subscribers.
Close

Please fill out the form
to view the full content

Please sign up to view the post..
* Required
Privacy Policy
close

SECURITY REPORT

Your valuable comments contribute to protecting Samsung Biologic’s core technology and management information, as well as reinforcing domestic competency and economic development.

  • This page is created for reporting core technology and management information leakage.
  • The reported contents as well as the identity of the reporter are strictly secured.
THE MANUAL FOR SECURITY NOTIFICATION